{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:28:22Z","timestamp":1782181702955,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.hoc.2010.05.009","type":"journal-article","created":{"date-parts":[[2010,7,25]],"date-time":"2010-07-25T05:25:34Z","timestamp":1280035534000},"page":"755-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Agents for the Treatment of Heparin-Induced Thrombocytopenia"],"prefix":"10.1016","volume":"24","author":[{"given":"Theodore E.","family":"Warkentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A\u00a014-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib2","first-page":"132","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2010.05.009_bib3","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Warkentin","year":"2004","journal-title":"Chest"},{"issue":"Suppl 6","key":"10.1016\/j.hoc.2010.05.009_bib4","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.hoc.2010.05.009_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0002-9343(99)00124-2","article-title":"Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia","volume":"106","author":"Wallis","year":"1999","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.hoc.2010.05.009_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2010.05.009_bib7","series-title":"Heparin-induced thrombocytopenia","first-page":"319","article-title":"Danaparoid for the treatment of heparin-induced thrombocytopenia","author":"Chong","year":"2007"},{"key":"10.1016\/j.hoc.2010.05.009_bib8","series-title":"Heparin-induced thrombocytopenia","first-page":"345","article-title":"Lepirudin for the treatment of heparin-induced thrombocytopenia","author":"Greinacher","year":"2007"},{"key":"10.1016\/j.hoc.2010.05.009_bib9","series-title":"Heparin-induced thrombocytopenia","first-page":"379","article-title":"Argatroban therapy in heparin-induced thrombocytopenia","author":"Lewis","year":"2007"},{"key":"10.1016\/j.hoc.2010.05.009_bib10","series-title":"Heparin-induced thrombocytopenia","first-page":"409","article-title":"Bivalirudin for the treatment of heparin-induced thrombocytopenia","author":"Bartholomew","year":"2007"},{"key":"10.1016\/j.hoc.2010.05.009_bib11","series-title":"Heparin-induced thrombocytopenia","first-page":"441","article-title":"Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inhibitors","author":"Bradner","year":"2007"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","article-title":"Heparin-induced thrombocytopenia: pathogenesis and management","volume":"121","author":"Warkentin","year":"2003","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2010.05.009_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjmed.2008.03.012","article-title":"A\u00a0spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia","volume":"121","author":"Warkentin","year":"2008","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.hoc.2010.05.009_bib14","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1538-7836.2008.03040.x","article-title":"Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of \u2018spontaneous\u2019 HIT?","volume":"6","author":"Jay","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1538-7836.2008.03263.x","article-title":"Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery \u2018spontaneous\u2019 HIT?","volume":"7","author":"Pruthi","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tmrv.2006.05.001","article-title":"Testing for heparin-induced thrombocytopenia antibodies","volume":"20","author":"Warkentin","year":"2006","journal-title":"Transfus Med Rev"},{"issue":"8","key":"10.1016\/j.hoc.2010.05.009_bib17","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1538-7836.2007.02617.x","article-title":"Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4\/heparin antibodies of the IgG, IgM, and IgA classes","volume":"5","author":"Greinacher","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.hoc.2010.05.009_bib18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"17","key":"10.1016\/j.hoc.2010.05.009_bib19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1067\/mob.2001.114690","article-title":"Heparin-induced thrombocytopenia is rare in pregnancy","volume":"185","author":"Fausett","year":"2001","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.hoc.2010.05.009_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2010.05.009_bib22","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","article-title":"Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia","volume":"108","author":"Warkentin","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.athoracsur.2008.10.060","article-title":"Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?","volume":"87","author":"Warkentin","year":"2009","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1016\/j.hoc.2010.05.009_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.thromres.2007.11.007","article-title":"Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings","volume":"122","author":"Greinacher","year":"2008","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1538-7836.2009.03735.x","article-title":"Anti-PF4\/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization","volume":"8","author":"Warkentin","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.hoc.2010.05.009_bib26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.hoc.2010.05.009_bib29","first-page":"247","article-title":"Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib30","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V91.3.916","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis recognize different epitopes on heparin:platelet factor 4","volume":"91","author":"Suh","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2010.05.009_bib31","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.ATV.0000238350.89477.88","article-title":"Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies","volume":"26","author":"Greinacher","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"10.1016\/j.hoc.2010.05.009_bib32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2010.05.009_bib33","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/archinte.163.20.2518","article-title":"An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients","volume":"163","author":"Warkentin","year":"2003","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.hoc.2010.05.009_bib34","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2004-831039","article-title":"An overview of the heparin-induced thrombocytopenia syndrome","volume":"30","author":"Warkentin","year":"2004","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"10.1016\/j.hoc.2010.05.009_bib36","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","article-title":"Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia","volume":"84","author":"Warkentin","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1182\/blood.V98.4.1252","article-title":"Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8","volume":"98","author":"Arepally","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2010.05.009_bib38","series-title":"Heparin-induced thrombocytopenia","first-page":"21","article-title":"Clinical picture of heparin-induced thrombocytopenia","author":"Warkentin","year":"2007"},{"issue":"20","key":"10.1016\/j.hoc.2010.05.009_bib39","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2008-08-173062","article-title":"The temporal profile of the anti-PF4\/heparin immune response","volume":"113","author":"Greinacher","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2010.05.009_bib40","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood-2008-10-186064","article-title":"Studies of the immune response in heparin-induced thrombocytopenia","volume":"113","author":"Warkentin","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2010.05.009_bib41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.009_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-136-3-200202050-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia","volume":"136","author":"Rice","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.hoc.2010.05.009_bib43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM200303133481120","article-title":"Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin","volume":"348","author":"Warkentin","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2010.05.009_bib44","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1161\/01.CIR.0000147537.72829.1B","article-title":"Heparin-induced thrombocytopenia: diagnosis and management","volume":"110","author":"Warkentin","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.10181","article-title":"Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia","volume":"71","author":"Smythe","year":"2002","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib47","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1538-7836.2006.01875.x","article-title":"Should vitamin K be administered when HIT is diagnosed after administration of coumarin?","volume":"4","author":"Warkentin","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0887-7963(96)80001-0","article-title":"Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant\/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia","volume":"10","author":"Warkentin","year":"1996","journal-title":"Transfus Med Rev"},{"issue":"8 pt 1","key":"10.1016\/j.hoc.2010.05.009_bib49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/0003-4819-135-8_Part_1-200110160-00009","article-title":"Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2010.05.009_bib50","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"1649","article-title":"Heparin-induced thrombocytopenia","author":"Warkentin","year":"2006"},{"key":"10.1016\/j.hoc.2010.05.009_bib51","series-title":"Heparin-induced thrombocytopenia","first-page":"283","article-title":"Treatment of heparin-induced thrombocytopenia: an overview","author":"Greinacher","year":"2007"},{"issue":"10","key":"10.1016\/j.hoc.2010.05.009_bib52","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2005.01560.x","article-title":"Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin","volume":"3","author":"Prechel","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1538-7836.2007.02815.x","article-title":"Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence","volume":"6","author":"Socher","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V96.1.182","article-title":"Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation","volume":"96","author":"Newman","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib55","first-page":"819","article-title":"The direct thrombin inhibitor hirudin","volume":"99","author":"Greinacher","year":"2008","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.hoc.2010.05.009_bib56","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1538-7836.2008.03171.x","article-title":"Heparin-induced thrombocytopenia\u2014therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of PF4\/heparin complexes","volume":"6","author":"Krauel","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11 Pt 1 of 2","key":"10.1016\/j.hoc.2010.05.009_bib57","first-page":"827","article-title":"Desulfated heparin blocks platelet activation induced by HIT antibodies\/heparin. A new approach to patient management [abstract]","volume":"104","author":"Prechel","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib58","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1055\/s-0037-1616046","article-title":"Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study","volume":"86","author":"Chong","year":"2001","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2005.04.011","article-title":"Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and\/or coumarin explain the rapid shift in clinical practice during the 1990s","volume":"117","author":"Lubenow","year":"2006","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.hoc.2010.05.009_bib60","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0037-1615946","article-title":"A\u00a0comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia","volume":"85","author":"Farner","year":"2001","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.hoc.2010.05.009_bib61","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood.V78.9.2194.2194","article-title":"Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia","volume":"78","author":"Demers","year":"1991","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2010.05.009_bib62","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.009_bib64","doi-asserted-by":"crossref","unstructured":"Salem M, Elrefai S, Shrit MA, et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by catastrophic stroke. Thromb Haemost 2010, in press.","DOI":"10.1160\/TH10-05-0284"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1055\/s-0037-1616573","article-title":"Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux","volume":"93","author":"Kuo","year":"2005","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.009_bib66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1160\/TH07-04-0252","article-title":"Fondaparinux for the treatment of patients with\u00a0acute heparin-induced thrombocytopenia","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.009_bib67","doi-asserted-by":"crossref","unstructured":"Grouzi E, Kyriakou E, Panagou I, et\u00a0al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2009. [Epub ahead of print].","DOI":"10.1177\/1076029609347900"},{"issue":"11","key":"10.1016\/j.hoc.2010.05.009_bib68","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1538-7836.2005.01620.x","article-title":"Lepirudin: is the approved dosing schedule too high?","volume":"3","author":"Hacquard","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"10.1016\/j.hoc.2010.05.009_bib69","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia\u2014results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"10.1016\/j.hoc.2010.05.009_bib70","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2004-02-0621","article-title":"Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies","volume":"104","author":"Lubenow","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib71","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2006-02-001057","article-title":"Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin","volume":"108","author":"Tardy","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2010.05.009_bib72","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hoc.2010.05.009_bib73","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.hoc.2010.05.009_bib74","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1378\/chest.129.6.1407","article-title":"Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia","volume":"129","author":"Lewis","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.hoc.2010.05.009_bib75","first-page":"958","article-title":"Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation","volume":"94","author":"Warkentin","year":"2005","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hoc.2010.05.009_bib76","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1592\/phco.26.4.452","article-title":"Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and\/or renal dysfunction","volume":"26","author":"Kaiser","year":"2006","journal-title":"Pharmacotherapy"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858810000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858810000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:54:15Z","timestamp":1760183655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858810000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0889858810000882"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2010.05.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agents for the Treatment of Heparin-Induced Thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2010.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}